ArticleCell biomaterials2026
A hybrid polymeric system for pulmonary mRNA delivery: Advancing mucosal vaccine development.
Article in Cell biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Optimization of Therapeutic modRNA Delivery to the Lung for Prevention of Pulmonary Fibrosis.Pharmaceutics · 2026Article
- Review
- Protocol for co-culture of murine bone marrow-derived dendritic cells with OT-I mouse CD8STAR protocols · 2026Article
- Stabilization strategies and advancements in lyophilization to preserve integrity and efficacy of next-generation biologicals.International journal of pharmaceutics: X · 2026Review
- mRNA Delivery by Lipoamino Fatty Acid-Peptide Polyplexes in Different Lung Cell Models and Lungs.Polymers · 2026Article
- Enhancement of Therapeutic mRNA Translation in Cellular Stress Conditions.International journal of molecular sciences · 2026Review
- RNA-Loaded Nanoparticles for Targeted Lung Delivery.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective pulmonary messenger RNA (mRNA) vaccination requires delivery systems capable of overcoming the airway barrier and efficiently transfecting pulmonary antigen-presenting cells. Here, we developed a hybrid polymeric system incorporating poly(lactic-co-glycolic) acid (PLGA) and poly(β-amino esters) (PBAEs) to enhance pulmonary mRNA delivery. The components acted through a spatiotemporally coordinated cascade: early PLGA hydrolysis acidified endosomes, boosting PBAE protonation and tightening mRNA condensation for protection; increased buffering, driven by accelerated protonation, strengthened proton-sponge-mediated escape; and weakened electrostatic interactions in the cytosol enabled rapid mRNA release and translation in dendritic cells, supporting immune activation. These findings highlight the need to balance endosomal escape with timely mRNA release for functional expression. The system also overcame the mucus barrier and enabled mRNA transfection in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.